Zydus Cadila gets USFDA nod for kidney stone tablets

Ahmedabad-based pharmaceutical major Zydus Cadila has received the final approval from the US drug regulator to market Potassium Citrate tablets that are used in the prevention of kidney stones.

The company today said in a statement here that it has received the nod from the US Food and Drug Administration (USFDA) to market Potassium Citrate tablets in strengths of 5,10 and 15 mEq. "The estimated sales in 2014 for Potassium Citrate ER Tablets is $ 131.7 million, as per IMS," the statement said.

The group now has 94 approvals and has so far filed 239 ANDAs since the commencement of the filing process in FY 2003-04.